Skip to search formSkip to main contentSkip to account menu

CHF 2819

Known as: CHF-2819, CHF2819 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Cyclic N-OxidesPhenylcarbamates

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Neurochemical and neurobehavioral effects of ganstigmine (CHF2819), a novel acetylcholinesterase inhibitor, in rat prefrontal cortex: an in vivo study.
2006
2006
Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug ganstigmine (CHF-2819).
Ganstigmine is an orally active, geneserine derived, carbamate-based acetylcholinesterase inhibitor developed for the treatment… 
Review
2006
Review
2006
CHF2819: pharmacological profile of a novel acetylcholinesterase inhibitor.
CHF2819 is a novel orally active acetylcholinesterase inhibitor (AChEI) developed for the treatment of Alzheimer's disease (AD… 
2005
2005
Strutture cristallografiche di complessi tra l’Acetilcolinesterasi da Torpedo Californica e quattro nuovi inibitori, potenziali farmaci per l’Alzheimer
E’ stato dimostrato che i sintomi del morbo di Alzheimer sono associati ad un deficit della funzione colinergica a livello… 
2004
2004
Ganstigmine and donepezil improve neurodegeneration in AD11 antinerve growth factor transgenic mice
Ganstigmine (CHF2819) is an acetylcholinesterase inhibitor that increases acetylcholine in rat hippocampus and ameliorates… 
2003
2003
The protective effect of ganstigmine against amyloid beta25–35 neurotoxicity on chicken cortical neurons is independent from the cholinesterase inhibition
2003
2003
Characterization of the effect of ganstigmine (CHF2819) on amyloid precursor protein metabolism in SH-SY5Y neuroblastoma cells
Summary. We have investigated the effect of ganstigmine (CHF2819), a novel geneserine derived acetylcholinesterase (AChE… 
Review
2003
Review
2003
Ganstigmine. Chiesi.
Ganstigmine (CHF-2819) is being developed by Chiesi as a potential treatment for neurodegenerative and cognitive disorders. The… 
2001
2001
Effects of ENA713 and CHF2819, two anti-Alzheimer’s disease drugs, on rat amino acid levels
2000
2000
Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease.
1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo¿2,3-bĭndol-5-ol 2-ethylphenylcarbamate N-oxide hydrochloride (3aS-cis) (CHF2819… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)